LogicBio Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

LogicBio Therapeutics (Nasdaq:LOGC) announced its president and CEO, Frederic Chereau, will participate in two upcoming investor conferences. The Barclays Gene Editing & Gene Therapy Summit features a fireside chat on November 15, 2021, at 8:00 a.m. ET. The Jefferies Virtual London Healthcare Conference will have a pre-recorded presentation available starting at 3:00 a.m. ET on November 18, 2021. Both events will be accessible via the Company’s website for 30 days. LogicBio focuses on genetic medicine targeting rare diseases with innovative gene editing and delivery technologies.

LEXINGTON, Mass., Nov. 11, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Frederic Chereau, will participate at the following upcoming investor conferences:

• Barclays Gene Editing & Gene Therapy Summit: Fireside chat at 8:00 a.m. ET on Monday, November 15, 2021
• Jefferies Virtual London Healthcare Conference: Pre-recorded corporate presentation will be available beginning at 3:00 a.m. ET on Thursday, November 18, 2021

A live webcast of the Barclays Gene Editing & Gene Therapy Summit fireside chat and a webcast replay of the Jefferies London presentation will be made available on the Investors section of the Company's website at https://investor.logicbio.com. The webcasts will be available for approximately 30 days.

About LogicBio Therapeutics 
LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering genome editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood. The company's genome editing platform, GeneRide™, is a new approach to precise gene insertion harnessing a cell's natural DNA repair process potentially leading to durable therapeutic protein expression levels. The company's gene delivery platform, sAAVy™, is an adeno-associated virus (AAV) capsid engineering platform designed to optimize gene delivery for treatments in a broad range of indications and tissues. The company is based in Lexington, MA. For more information, visit www.logicbio.com, which does not form a part of this release.

Investor Contacts: 

Laurence Watts
Gilmartin Group
(619) 916-7620
laurence@gilmartinir.com 

Stephen Jasper
Gilmartin Group
(858) 525-2047
stephen@gilmartinir.com 

Media Contacts:
Adam Daley
Berry & Company Public Relations
W:212-253-8881
C: 614-580-2048
adaley@berrypr.com

View original content:https://www.prnewswire.com/news-releases/logicbio-therapeutics-to-participate-in-upcoming-investor-conferences-301422553.html

SOURCE LogicBio Therapeutics, Inc.

FAQ

What is the schedule for LogicBio Therapeutics at the Barclays Gene Editing Summit?

LogicBio Therapeutics will have a fireside chat at the Barclays Gene Editing & Gene Therapy Summit on November 15, 2021, at 8:00 a.m. ET.

When will the Jefferies Virtual London Healthcare Conference presentation be available for LogicBio Therapeutics?

The pre-recorded corporate presentation for LogicBio Therapeutics will be available starting at 3:00 a.m. ET on November 18, 2021.

Where can I watch the webcasts for LogicBio Therapeutics' investor conferences?

Webcasts for the Barclays Summit and Jefferies Conference will be available on LogicBio's investor website for approximately 30 days.

What does LogicBio Therapeutics focus on?

LogicBio Therapeutics specializes in genetic medicine, particularly in genome editing and gene delivery for treating rare and serious diseases.